Vision
Salubris is committed to becoming China's most influential innovative global pharma
Mission
Salubris focuses on improving people's lives with exceptional medicines
Values
We believe Keeping Promises is the Source of Happiness; We provide value by focusing on patient needs; Our determination is our foundation.
Our core competitiveness arises from high-quality innovative products and marketing driven by robust clinical trials and evidence-based medicine. Our primary therapeutic area focus is cardiovascular and cerebrovascular disease, with active expansion into diabetes, oncology, orthopedics and infectious disease. Through in-house R&D, partnerships, strategic investments, and acquisitions, we are rapidly enriching our pipeline, developing multiple blockbuster products, and building a fully integrated pharmaceutical ecosystem. Guided by unified purpose and international expansion, we will continue to build our high-caliber team.
We have extensive product portfolioses of innovative and established medicines involved in fields of cardiovascular and cerebrovascular diseases, diabetes, osteoporosis, tumors, etc. The product portfolioses are used for 4 fields and 6 divisions of cardio-cerebrovascular therapy, and provide patients with high-quality and comprehensive therapy options.
We focus on the research and development, production and sales of high-end interventional medical devices. The product pipeline covers key areas of interventional therapy such as cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology and cardiac rhythm management. We practice the core values of "patient-centered" and the corporate philosophy of "beauty comes from honesty", insist on continuous investment in product research and development and technological innovation, create efficient and high-quality innovative medical device products, realize strategic coordination among devices, medicines and services, and strive to become the world's leading platform-based enterprise of innovative cardiovascular and cerebrovascular devices.
Accurate layout of global industrial chain with technical cooperation, investment acquisition and other approaches under the guidance of collectivization and internationalization.
